Which medication is associated with nasopharyngitis and hypersensitivity as adverse effects?

Which medication is associated with nasopharyngitis and hypersensitivity as adverse effects?

• A. Eptinezumab (Vyepti)
• B. Fremanezumab
• C. Rimegepant
• D. Topiramate

Answer: (A)

Understanding adverse effects of CGRP pathway–targeted therapies helps explain why this medication fits the pattern. Monoclonal antibodies against CGRP, used for migraine prevention, often share inflammatory-related reactions as part of their safety profile. Nasopharyngitis is a common, expected side effect with these biologics due to their impact on mucosal tissues and immune signaling. Hypersensitivity reactions, while rarer, are documented with this class as well because, being a protein-based therapeutic, they can trigger allergic-type responses in some individuals. Eptinezumab, given by IV infusion, has both nasopharyngitis and hypersensitivity listed in its safety data. That combination of adverse effects is most characteristic of this class and route, making it the best match among the options. Rimegepant is a CGRP receptor antagonist taken orally and tends to cause upper gastrointestinal or hepatic-related effects rather than classic hypersensitivity issues. Topiramate is a broad antiepileptic agent with cognitive effects, paresthesias, and kidney stones—not a CGRP monoclonal antibody. Fremanezumab, another CGRP mAb, can have similar mucosal and hypersensitivity effects, but the question’s pairing is most directly aligned with the labeled profile of the IV CGRP antibody presented here.

Understanding adverse effects of CGRP pathway–targeted therapies helps explain why this medication fits the pattern. Monoclonal antibodies against CGRP, used for migraine prevention, often share inflammatory-related reactions as part of their safety profile. Nasopharyngitis is a common, expected side effect with these biologics due to their impact on mucosal tissues and immune signaling. Hypersensitivity reactions, while rarer, are documented with this class as well because, being a protein-based therapeutic, they can trigger allergic-type responses in some individuals.

Eptinezumab, given by IV infusion, has both nasopharyngitis and hypersensitivity listed in its safety data. That combination of adverse effects is most characteristic of this class and route, making it the best match among the options.

Rimegepant is a CGRP receptor antagonist taken orally and tends to cause upper gastrointestinal or hepatic-related effects rather than classic hypersensitivity issues. Topiramate is a broad antiepileptic agent with cognitive effects, paresthesias, and kidney stones—not a CGRP monoclonal antibody. Fremanezumab, another CGRP mAb, can have similar mucosal and hypersensitivity effects, but the question’s pairing is most directly aligned with the labeled profile of the IV CGRP antibody presented here.